# Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab

> **NCT01223235** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Fallopian Tubes Cancer
- Ovarian Cancer
- Peritoneal Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821

## Key facts

- **NCT ID:** NCT01223235
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01223235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01223235, "Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01223235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*